Developer docs
API playgroundTry for free, no card

Search company profiles

Kester Capital

Full company profile

uuid00057js

Namestring
Kester Capital
Legal namestring
Kester Capital LLP
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Kester Capital is a London-based private equity firm operating as Kester Capital LLP, founded in 2013 and headquartered at 14-16 Bruton Place in Mayfair. The firm invests exclusively in two sectors — Technology and Life Sciences — targeting equity investments of up to £75 million in mid-market primary buyouts alongside ambitious management teams. Its investment focus spans B2B software (e.g., Optibrium's AI-enabled drug discovery platform, Re-flow field service management software, Addresscloud geospatial risk analytics), data and information services (Vixio regulatory intelligence, DC Byte data centre market intelligence, Nutritics food data), and Life Sciences services (Evestia Clinical CRO, GXP Engaged GxP auditing, Kintiga market access consulting, Rephine GMP/GCP auditing). The firm manages four funds; Fund IV closed at a £425m hard cap in November 2025, more than double Fund III's £200m close in March 2024, with both materially oversubscribed.

Kester generates revenue through two streams typical of private equity fund managers: (1) recurring management fees on committed capital across its fund series, and (2) carried interest on investment returns above preferred return thresholds. The firm has demonstrated an exceptional and consistent exit record — four consecutive exits above 4x (including Avania at 8.4x, Vixio at 4.8x, Atec at 4x and Jollyes at 4.3x) and eight consecutive exits above 3x — alongside portfolio-level revenue scaling such as Avania's >5x revenue growth, Atec's 3x revenue / 4x profit, and Vixio's >60% IRR with NRR>100%. Operating geographies for portfolio companies span the UK, continental Europe, the US, Asia Pacific (NZ, India), and Turkey.

The firm's distribution model is direct and relationship-driven: investment opportunities are originated by Kester's own sector-specialist professionals, and fund capital is sourced directly from blue-chip institutional LPs (pension funds, endowments, foundations, family offices) across the US, Europe and Asia without intermediaries. Portfolio-level technology stack is heterogenous across holdings, ranging from AI-powered drug discovery platforms and geospatial risk models to subscription regulatory information services and GxP audit management tools. The Kester Foundation, established in 2022, receives 10% of carry from Fund III onwards and supports charitable causes including the Francis Crick Institute, the Sutton Trust and The Fore.

Short descriptiontext

Kester Capital is a London-based private equity firm focused exclusively on Technology and Life Sciences. It deploys equity investments of up to £75 million in mid-market primary buyouts, currently investing from its £425 million Fund IV across B2B software, data services, and life sciences businesses.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices10 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
private equity investing, mid-market buyouts, technology sector investments, life sciences investments, growth capital
Industry2 codes
PRIMARYFSANABAA
Large-Cap / Mega-Fund Buyout
SECONDARYBPAHADAB
Corporate Finance & Capital Advisory
NAICS code1 code
  • Other Investment Pools and Funds5259
SIC code1 code
  • Security Brokers, Dealers & Flotation Companies6211
Product category
Private Equity Investing
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Management Fees
TypeSubscription Recurring
Description

Kester Capital generates management fees on its committed capital under management across its funds (Fund I through Fund IV). Fees are charged on committed capital throughout the investment period.

kestercapital.com
2Carried Interest (Performance Fees)
TypeUsage Based
Description

Kester Capital earns carried interest on investment returns above preferred return thresholds. The firm has delivered exceptional returns including four consecutive exits over 4x and eight consecutive exits over 3x. The Kester Foundation receives 10% of carry generated by Fund III and future funds.

kestercapital.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Others
Pricing details1 tier
1Fund IV – £425 million hard cap (2025)
ModelOtherBilling cadenceMulti-year contract
Notes

Kester Capital Fund IV held first and final close at £425 million hard cap in November 2025, materially oversubscribed. Fund IV is more than double the size of Fund III (£200m).

kestercapital.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1Kester Foundation
Description

A registered charitable foundation established in 2022 that uses its share of carried interest to support third party charities and not-for-profit entities including The Francis Crick Institute, The Sutton Trust, and The Fore.

kestercapital.com
Core offering1 text field

Kester Capital is a UK mid-market private equity firm that invests equity of up to £75 million in primary buyouts of ambitious Technology and Life Sciences businesses. The firm operates sector-focused funds (currently Fund III and Fund IV) that partner with management teams and founders to scale high-growth businesses into market leaders, generating returns through management fees on committed capital and carried interest on successful exits.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Kester has delivered four consecutive exits over 4x and eight consecutive exits over 3x across its fund history.
+5 more records
Product overview1 text field

Kester Capital is a UK-based private equity firm offering equity investments of up to £75 million to ambitious Technology and Life Sciences businesses. The firm operates a platform investment approach across two sectors: Technology (including Software, Data & Information Services, and Tech-enabled Services) and Life Sciences (including CRO services, GxP auditing, and market access consulting). The portfolio includes B2B SaaS platforms (Nutritics, Addresscloud, Re-flow), data and information services (DC Byte, VIXIO, Optibrium), and specialised healthcare services (Evestia Clinical, GXP Engaged, Kintiga, Rephine), with former investments including Avania (medtech CRO) and The Boundary (architectural visualisation software).

Product and service4 records
1Kester Capital Fund IV
CategoryPrivate Equity Fund (Flagship)
Description

Kester Capital's fourth flagship private equity fund, focused on Technology and Life Sciences, targeting equity investments of up to £75 million per transaction. Investors (LPs) commit capital to the closed-end fund and receive carried interest-style returns on successful exits.

2Kester Capital Fund III
CategoryPrivate Equity Fund (Flagship)
Description

Kester Capital's third flagship private equity fund, deployed into Technology and Life Sciences primary buyouts, with 10% of carried interest committed to the Kester Foundation.

3Technology Sector Investment Services
CategorySector Investment Programme
Description

Equity investments of up to £75 million in Technology businesses across three sub-verticals: B2B Software (horizontal or vertical applications solving complex problems), Data & Information Services (subscription-based data and insight providers with clear IP), and Tech-enabled Services (technology-enabled B2B services in high-growth markets with scalable models).

4Life Sciences Sector Investment Services
CategorySector Investment Programme
Description

Equity investments in providers of outsourced services, products and technology to pharma, biotech and medtech customers with strong scientific, regulatory and technical expertise, supporting them through global scaling, C-suite capability building, operational professionalisation, and strategic acquisitions.

Scale indicator16 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierMinorTypeOthers
Description

The Kester Foundation (established 2022) supports The Francis Crick Institute, a biomedical research facility focused on understanding how living things work and driving benefits for human health.

Strategic tierMinorTypeOthers
Description

The Kester Foundation supports The Sutton Trust, the UK's leading social mobility charity, which empowers young people to access life-changing opportunities through programmes and research.

3The Fore
Strategic tierMinorTypeOthers
Description

The Kester Foundation supports The Fore, the only venture philanthropy fund in the UK dedicated to small charities, focused on helping the best solutions scale from grassroots to nationwide impact.

kestercapital.com
Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

UK mid-market private equity firm with a long-standing focus on software, tech-enabled services, and specialist B2B businesses — closely matching Kester's Tech vertical and mid-market equity cheque size.

TypeDirect peer
Description

One of the most active UK mid-market private equity investors with broad sector exposure including technology and healthcare services, operating with a comparable mid-market equity ticket to Kester Capital.

TypeDirect peer
Description

UK smaller-mid-market private equity firm investing in tech-enabled, B2B services, and specialist software businesses — comparable to Kester in deal approach, though typically at the smaller end of the equity-cheque range.

4Lyceum Capital
TypeDirect peer
Description

UK mid-market private equity firm focused on software, technology-enabled services, and data businesses — a close peer to Kester on the Technology side of its investment strategy.

5Livingbridge
TypeDirect peer
Description

UK mid-market growth and private equity firm investing in software, tech-enabled services, and consumer, with a focus and engagement model very similar to Kester's sector-specialist approach.

TypeDirect peer
Description

UK mid-market private equity firm focused on software, services, and life sciences, with a similar sweet-spot equity cheque size and a comparable sector-specialist investment thesis to Kester Capital.

TypeDirect peer
Description

UK mid-market private equity firm investing in growth-oriented, tech-enabled, and consumer-facing businesses, with comparable equity cheque sizes and sector breadth to Kester Capital.

TypeRegional player
Description

European mid-market private equity firm focused on business services, technology, and specialist industrials — a regional European competitor with overlapping interest in Kester's Tech-enabled Services and data subsectors.

TypeBroad incumbent
Description

Large European mid-market private equity investor with a diversified sector mandate including technology, healthcare, and business services — a broader incumbent that competes with Kester for select assets, especially in Life Sciences services.

TypeBroad incumbent
Description

A larger UK-headquartered technology and software-focused private equity firm; a broader incumbent that operates in the same B2B software and tech-enabled services space as Kester but at materially greater scale and AUM.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles16 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A13 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment12 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Kester Capital

Private Equity Investingkestercapital.com

Kester Capital is a London-based private equity firm focused exclusively on Technology and Life Sciences. It deploys equity investments of up to £75 million in mid-market primary buyouts, currently investing from its £425 million Fund IV across B2B software, data services, and life sciences businesses.

What Kester Capital does

Kester Capital is a London-based private equity firm operating as Kester Capital LLP, founded in 2013 and headquartered at 14-16 Bruton Place in Mayfair. The firm invests exclusively in two sectors — Technology and Life Sciences — targeting equity investments of up to £75 million in mid-market primary buyouts alongside ambitious management teams. Its investment focus spans B2B software (e.g., Optibrium's AI-enabled drug discovery platform, Re-flow field service management software, Addresscloud geospatial risk analytics), data and information services (Vixio regulatory intelligence, DC Byte data centre market intelligence, Nutritics food data), and Life Sciences services (Evestia Clinical CRO, GXP Engaged GxP auditing, Kintiga market access consulting, Rephine GMP/GCP auditing). The firm manages four funds; Fund IV closed at a £425m hard cap in November 2025, more than double Fund III's £200m close in March 2024, with both materially oversubscribed.

Kester generates revenue through two streams typical of private equity fund managers: (1) recurring management fees on committed capital across its fund series, and (2) carried interest on investment returns above preferred return thresholds. The firm has demonstrated an exceptional and consistent exit record — four consecutive exits above 4x (including Avania at 8.4x, Vixio at 4.8x, Atec at 4x and Jollyes at 4.3x) and eight consecutive exits above 3x — alongside portfolio-level revenue scaling such as Avania's >5x revenue growth, Atec's 3x revenue / 4x profit, and Vixio's >60% IRR with NRR>100%. Operating geographies for portfolio companies span the UK, continental Europe, the US, Asia Pacific (NZ, India), and Turkey.

The firm's distribution model is direct and relationship-driven: investment opportunities are originated by Kester's own sector-specialist professionals, and fund capital is sourced directly from blue-chip institutional LPs (pension funds, endowments, foundations, family offices) across the US, Europe and Asia without intermediaries. Portfolio-level technology stack is heterogenous across holdings, ranging from AI-powered drug discovery platforms and geospatial risk models to subscription regulatory information services and GxP audit management tools. The Kester Foundation, established in 2022, receives 10% of carry from Fund III onwards and supports charitable causes including the Francis Crick Institute, the Sutton Trust and The Fore.

Kester Capital firmographics

Firmographics
Name
Kester Capital
Legal name
Kester Capital LLP
Website
https://kestercapital.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Short description
Kester Capital is a London-based private equity firm focused exclusively on Technology and Life Sciences. It deploys equity investments of up to £75 million in mid-market primary buyouts, currently investing from its £425 million Fund IV across B2B software, data services, and life sciences businesses.
Ownership category
akta.pro rank

Kester Capital industry classification

Industry
Product category
Private Equity Investing
NAICS
Other Investment Pools and Funds (5259)
SIC
Security Brokers, Dealers & Flotation Companies (6211)
akta.pro industry
PRIMARYFSANABAA
Large-Cap / Mega-Fund Buyout
SECONDARYBPAHADAB
Corporate Finance & Capital Advisory

Keywords

  • Private equity investing
  • Mid-market buyouts
  • Technology sector investments
  • Life sciences investments
  • Growth capital

Where Kester Capital is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices10 records

Markets served

Kester Capital business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

  1. Management Fees: Kester Capital generates management fees on its committed capital under management across its funds (Fund I through Fund IV). Fees are charged on committed capital throughout the investment period.
  2. Carried Interest (Performance Fees): Kester Capital earns carried interest on investment returns above preferred return thresholds. The firm has delivered exceptional returns including four consecutive exits over 4x and eight consecutive exits over 3x. The Kester Foundation receives 10% of carry generated by Fund III and future funds.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractFund IV – £425 million hard cap (2025)

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Kester Capital product offering

Product offering

Core offering

Kester Capital is a UK mid-market private equity firm that invests equity of up to £75 million in primary buyouts of ambitious Technology and Life Sciences businesses. The firm operates sector-focused funds (currently Fund III and Fund IV) that partner with management teams and founders to scale high-growth businesses into market leaders, generating returns through management fees on committed capital and carried interest on successful exits.

Product overview

Kester Capital is a UK-based private equity firm offering equity investments of up to £75 million to ambitious Technology and Life Sciences businesses. The firm operates a platform investment approach across two sectors: Technology (including Software, Data & Information Services, and Tech-enabled Services) and Life Sciences (including CRO services, GxP auditing, and market access consulting). The portfolio includes B2B SaaS platforms (Nutritics, Addresscloud, Re-flow), data and information services (DC Byte, VIXIO, Optibrium), and specialised healthcare services (Evestia Clinical, GXP Engaged, Kintiga, Rephine), with former investments including Avania (medtech CRO) and The Boundary (architectural visualisation software).

Differentiator

Problem solved

Functional benefit

Brands

  • Kester Foundation: A registered charitable foundation established in 2022 that uses its share of carried interest to support third party charities and not-for-profit entities including The Francis Crick Institute, The Sutton Trust, and The Fore.

Products and services

  • Kester Capital Fund IV Kester Capital's fourth flagship private equity fund, focused on Technology and Life Sciences, targeting equity investments of up to £75 million per transaction. Investors (LPs) commit capital to the closed-end fund and receive carried interest-style returns on successful exits.
  • Kester Capital Fund III Kester Capital's third flagship private equity fund, deployed into Technology and Life Sciences primary buyouts, with 10% of carried interest committed to the Kester Foundation.
  • Technology Sector Investment Services Equity investments of up to £75 million in Technology businesses across three sub-verticals: B2B Software (horizontal or vertical applications solving complex problems), Data & Information Services (subscription-based data and insight providers with clear IP), and Tech-enabled Services (technology-enabled B2B services in high-growth markets with scalable models).
  • Life Sciences Sector Investment Services Equity investments in providers of outsourced services, products and technology to pharma, biotech and medtech customers with strong scientific, regulatory and technical expertise, supporting them through global scaling, C-suite capability building, operational professionalisation, and strategic acquisitions.

Quantifiable outcome

  • Kester has delivered four consecutive exits over 4x and eight consecutive exits over 3x across its fund history.
  • +5 more outcomes

Companies that use Kester Capital

Customer profile

Named customers5 records

Segments5 records

Ideal customer profiles2 records

Kester Capital technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature4 records

Kester Capital partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered minor.

  • The Francis Crick InstituteminorOthersThe Kester Foundation (established 2022) supports The Francis Crick Institute, a biomedical research facility focused on understanding how living things work and driving benefits for human health.
  • The Sutton TrustminorOthersThe Kester Foundation supports The Sutton Trust, the UK's leading social mobility charity, which empowers young people to access life-changing opportunities through programmes and research.
  • The ForeminorOthersThe Kester Foundation supports The Fore, the only venture philanthropy fund in the UK dedicated to small charities, focused on helping the best solutions scale from grassroots to nationwide impact.

Scale indicators16 records

Recent moves9 records

Expansion highlights6 records

Kester Capital competitors and assessment

Company assessment

Direct peers

  • ECI Partners: UK mid-market private equity firm with a long-standing focus on software, tech-enabled services, and specialist B2B businesses — closely matching Kester's Tech vertical and mid-market equity cheque size.
  • LDC (Lloyds Development Capital): One of the most active UK mid-market private equity investors with broad sector exposure including technology and healthcare services, operating with a comparable mid-market equity ticket to Kester Capital.
  • Mobeus Equity Partners: UK smaller-mid-market private equity firm investing in tech-enabled, B2B services, and specialist software businesses — comparable to Kester in deal approach, though typically at the smaller end of the equity-cheque range.
  • Lyceum Capital: UK mid-market private equity firm focused on software, technology-enabled services, and data businesses — a close peer to Kester on the Technology side of its investment strategy.
  • Livingbridge: UK mid-market growth and private equity firm investing in software, tech-enabled services, and consumer, with a focus and engagement model very similar to Kester's sector-specialist approach.
  • Inflexion: UK mid-market private equity firm focused on software, services, and life sciences, with a similar sweet-spot equity cheque size and a comparable sector-specialist investment thesis to Kester Capital.
  • Phoenix Equity Partners: UK mid-market private equity firm investing in growth-oriented, tech-enabled, and consumer-facing businesses, with comparable equity cheque sizes and sector breadth to Kester Capital.

Regional players

  • Stirling Square Capital Partners: European mid-market private equity firm focused on business services, technology, and specialist industrials — a regional European competitor with overlapping interest in Kester's Tech-enabled Services and data subsectors.

Broad incumbents

  • Bridgepoint: Large European mid-market private equity investor with a diversified sector mandate including technology, healthcare, and business services — a broader incumbent that competes with Kester for select assets, especially in Life Sciences services.
  • Hg (Hg Capital): A larger UK-headquartered technology and software-focused private equity firm; a broader incumbent that operates in the same B2B software and tech-enabled services space as Kester but at materially greater scale and AUM.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Kester Capital social profiles

Digital presence

Kester Capital compliance and trust

Trust signal

Compliance1 record

Kester Capital financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Kester Capital leadership team

Management profile

Number of profiles

Profiles16 records

Kester Capital subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Kester Capital funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Kester Capital M&A and investment

M&A and investment

M&A13 records

Investments12 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kester Capital

What does Kester Capital do?

Kester Capital is a UK mid-market private equity firm that invests equity of up to £75 million in primary buyouts of ambitious Technology and Life Sciences businesses. The firm operates sector-focused funds (currently Fund III and Fund IV) that partner with management teams and founders to scale high-growth businesses into market leaders, generating returns through management fees on committed capital and carried interest on successful exits.

Is Kester Capital a public or private company?

Kester Capital is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Kester Capital founded?

Kester Capital was founded in 2013. It employs 11 to 50 people.

Where is Kester Capital based?

Kester Capital is headquartered in London, United Kingdom, in the Europe region.

How does Kester Capital make money?

Two revenue lines are on record. Management Fees are the primary driver. The others are carried Interest (Performance Fees).

Who are Kester Capital's main competitors?

Direct peers on record are ECI Partners, LDC (Lloyds Development Capital), Mobeus Equity Partners, Lyceum Capital, Livingbridge, Inflexion and Phoenix Equity Partners. Stirling Square Capital Partners is listed as a regional player. Broad incumbents are Bridgepoint and Hg (Hg Capital).

Does Kester Capital have an API?

No public API is recorded for Kester Capital.

What industry is Kester Capital in?

Kester Capital's product category is Private Equity Investing. Its primary akta.pro industry code is FSANABAA, Large-Cap / Mega-Fund Buyout, with a secondary code of BPAHADAB, Corporate Finance & Capital Advisory. Its NAICS code is 5259 and its SIC code is 6211.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
DcadvisoryDC Advisory acts as the exclusive financial advisor to Kester Capital on its investment in NutriticsIn January 2026, Kester Capital announced a minority investment in Nutritics, a Dublin-based food data management software platform serving the foodservice and hospitality sectors. DC Advisory acted as the exclusive financial advisor to Kester Capital on the transaction, providing buy-side M&A support including valuation, strategic growth assessment, and market intelligence. With Kester's backing, Nutritics aims to accelerate growth, drive product development, and expand into the US market both organically and through acquisitions.Pulse 2.0Kester Closes Fourth Private Equity Fund At £425 MillionKester, a London-based private equity firm, has completed the first and final close of Kester Capital Fund IV at its hard cap of £425 million after a four-month fundraising period, more than doubling the £200 million raised by its previous fund. The latest fund attracted blue-chip institutional investors across the United States, Europe, and Asia, reflecting strong confidence in the firm's thematic investment approach and track record of generating multiple exits exceeding three times return. Fund IV will continue the firm's strategy of investing in rapidly expanding Technology and Life Sciences companies, building on recent investments in Addresscloud, Re-flow, and Evestia Clinical.Re-FlowRe-flow secures investment from Kester Capital to drive…Re-flow, a field management software provider for critical infrastructure, secured a strategic investment from Kester Capital. The investment will accelerate growth, new product development, and market expansion in the UK and internationally. The company aims to capitalize on rising demand for digital FM solutions.GlobeNewswireBionical Emas sells EMAS Pharma to Kester Capital following strategic reviewBionical Emas is selling its Clinical Development division, EMAS Pharma, to Kester Capital and an incoming executive team after a strategic review. The sale will let the company focus on its core Early Access Programs and Clinical Trial Supply businesses and invest in global expansion. CEO Tom Watson said the move will accelerate its ambition to help more patients.GlobeNewswireKester Capital backs experienced management team in acquiring EMAS PharmaKester Capital, a UK private equity firm, acquired EMAS Pharma, a clinical research organization, from Bionical Emas. The deal includes a new senior management team and plans for organic and acquisition-driven growth. The global CRO market is projected to grow from £64 billion in 2024 to £139 billion by 2032.GlobeNewswireBionical Emas sells EMAS Pharma to Kester Capital following strategic reviewBionical Emas is selling its Clinical Development division, EMAS Pharma, to Kester Capital and an incoming executive team after a strategic review. Financial terms were not disclosed. The sale will let Bionical focus on its core Early Access Programs and Clinical Trial Supply businesses and invest in global expansion.BenzingaBionical Emas sells EMAS Pharma to Kester Capital following strategic reviewBionical Emas sold its Clinical Development division, EMAS Pharma, to Kester Capital and an incoming executive team after a strategic review. Financial terms were not disclosed. The sale will let Bionical focus on Early Access Programs and Clinical Trial Supply, with Richard Lambie joining the leadership team.GlobeNewswireKester Capital backs experienced management team in acquiring EMAS PharmaKester Capital, a UK private equity firm, acquired EMAS Pharma, a clinical research organization, from Bionical Emas. The deal includes a new senior management team and plans for organic and acquisition-driven growth. The global CRO market is projected to grow from £64 billion in 2024 to £139 billion by 2032.Pulse 2.0Kester Capital: Oversubscribed Third Fund Closed At £200 MillionKester Capital closed its third fund at £200 million, exceeding its £150 million target and hard cap. The fund focuses on primary buyouts in healthcare and tech, with 10% of carry going to the Kester Foundation. Abhishek Majumdar was promoted to partner.FinSMEsKester Capital Closes Fund III, at £200MKester Capital closed its Fund III at £200M, with new blue-chip institutional investors from the US, Europe, and UK. The fund targets primary buyouts in healthcare and technology, with investments of £10 to £40M. Abhishek Majumdar was promoted to Partner.